Date: 2013-12-03
Type of information: Production agreement
Compound: Fc-fusion protein for the treatment of asthma and other allergic diseases
Company: Royal DSM (The Netherlands) Tunitas Therapeutics (USA)
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Type agreement: development
production
manufacturing
Action mechanism:
Disease: asthma, other allergic diseases
Details: * On December 3, 2013, DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has announced that it has signed an agreement with Tunitas Therapeutics, an US early stage drug development company dedicated to the discovery and development of a broad platform of therapeutic proteins for allergies. The contract covers the initiation of process development activities by DSM for Tunitas\' lead Fc-fusion protein for the treatment of asthma and other allergic diseases. This project represents an agreement for DSM Biologics\' Groningen, The Netherlands, facility for development where the intended manufacturing site is DSM Biologics\' Brisbane, Australia, facility.
Financial terms: Financial terms were not disclosed.
Latest news:
